<DOC>
	<DOCNO>NCT02876198</DOCNO>
	<brief_summary>The intra-vitreous injection ( IVT ) anti-VEGF ( vascular endothelial growth factor ) currently standard treatment retinal neovascularization . The VEGF stimulate endothelial cell ' proliferation migration . It also increase microvascular permeability . If VEGFs prove efficiency decrease choroidal neovascular proliferation , impact head optic nerve 's microvasculature yet unknown . Knowing microvasculature provide retinal nerve fiber oxygen , locate area head optic nerve , vasoconstriction induce anti-VEGF may incidence loss retinal nerve fiber .</brief_summary>
	<brief_title>Study Modification Retinal Nerve Fiber Layer Patients Treated With Intravitreous Injection Anti-VEGF</brief_title>
	<detailed_description />
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Retinal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age â‰¥18 year old Patients treat antiVEGF accord French summary product characteristic ( SPC ) Patients informed trial oppose participate study Patients present retinal condition , include optic nerve Patients treat antiVEGF eye Myopia &lt; 3 Pregnant woman Lack affiliation social security universal health coverage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Retinal neovascularization</keyword>
	<keyword>Anti-VEGF</keyword>
	<keyword>Retinal Nerve Fiber Layer ( RNFL )</keyword>
</DOC>